NEW YORK, Sept.

COPENHAGEN, March 20 /PRNewswire/ -- Santaris Pharma announced today that the fourth LNA-based drug has been brought into the clinic.

Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) presented data from its pipeline programs at the 2008 EORTC-NCI-AACR (European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research) annual meeting in Geneva, Switzerland.

Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced today that Oncaspar-IV(TM), the next generation pegylated L-asparaginase, received approval from the Commission of the European Communities for designation as an orphan medicinal product.

Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) ("Enzon") announced today that it is exploring strategic alternatives for its specialty pharmaceuticals business.